Insider buying last 90 days
No open-market insider purchases were filed for GMED in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Globus Medical moves this week on third-quarter results and a lowered 2026 revenue outlook. The company reported Q3 2026 earnings that topped estimates, compared with $1.18 per share a year ago, while management cited continued declines at its Nevro business, delayed spine product launches, and lower contributions from competitive sales recruiting as reasons for the guidance cut and a shift in focus toward new products and growth opportunities in 2027. Alongside the results, Globus Medical announced a $500 million increase to its share repurchase program, and separate commentary described the company as the second-largest player in the spine industry with a narrow moat following its NuVasive merger and Nevro acquisition. The company is also set to participate in the Jefferies Global Healthcare Conference in London.
Shares closed at $76.37, up 7.5%, but remain below both the 50-day average of $77.07 and the 200-day average of $83.06, with the 50-day below the 200-day. The GekkoIndex reads 58.8, placing the stock in the Neutral zone, up 3.4 over five sessions. Price sits 0.4% below Gekko Fair Value of $76.66.
The next earnings date is 23 February 2027, outside a typical 20-day holding window. Over the last 90 days, Congress recorded 2 buys and 0 sells, while the last 30 days show 2 unusual options signals with put premium of $944,594 and no call premium. Seasonally, the next 20 trading days have averaged -0.2% over 5 years, rising in 3 of them, a mixed backdrop worth noting.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Globus Medical scores 3 supportive, 2 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed1 headwind
Below 50 and 200-day
Close $72.14 is below the 50-day ($76.55) and 200-day ($82.70) averages, and the 50-day is below the 200-day.
See the chart62.1, Accumulation
Reading 62.1 is in the Accumulation zone.
See the GekkoIndex0.1% above
Price is within 5% of Gekko Fair Value (0.1% above).
See fair valueMixed
Last 90 days: Congress 2 buys / 0 sales. Last 30 days: 2 unusual options signals.
See smart moneyReports in 100 days
Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.
See earnings+2.1% on average
From this point in the calendar, the next 20 trading days averaged +2.1% over 5 years, rising in 4 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Globus Medical closed at $72.14 on Nov 13, 2026, −14.8% over the past year, inside a 52-week range of $70.40 to $101.40.
Use the left and right arrow keys to read daily values.
Put GMED on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Globus Medical designs, builds, and sells medical devices used to treat disorders of the bones, joints, and spine. It is best known for its spinal care offerings, which range from fusion hardware such as pedicle screw and rod systems, plating systems, and spacers, to motion-preserving options like disc replacements and dynamic stabilization devices, along with tools for managing vertebral compression fractures.
Its product lines extend beyond the spine into orthopedic trauma care, with plates, screws, nails, and fixation systems for fractures, as well as joint reconstruction devices for the hip and knee, including stems, cups, and arthroplasty implants. The company also supplies regenerative biologic materials, such as allografts and synthetic substitutes, and distributes cell- and tissue-based products, serving patients and clinicians who treat musculoskeletal conditions such as degenerative disease, deformity, tumors, and trauma.
Globus Medical was founded in 2003 and is headquartered in Audubon, Pennsylvania. Its shares are listed on the NYSE under the ticker GMED.
Globus Medical’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 62.1, in the Accumulation zone, up 0.8 points over five sessions.
Up 0.8 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 48 | +1.5% | +2.3% | ||
| Accumulation (current zone) | 247 | +0.3% | +2.1% | ||
| Neutral | 345 | +0.3% | +1.9% | ||
| Distribution | 55 | +0.9% | −1.1% | ||
| Selling | 7 | Too few readings yet | |||
Average GMED share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Globus Medical trades 0.1% above Gekko Fair Value of $72.10, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Globus Medical shares are worth, recalculated every trading day.
$72.10
Gekko Fair Value, Nov 14, 2026
0.1% above fair value · About fair value
At the end of Aug 2026 the price was 12.2% above the estimate.
No open-market insider purchases were filed for Globus Medical, and members of Congress disclosed 2 purchases and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for GMED in the last 90 days.
From Form 4 filings, dated to when each was filed.
2trades disclosed: 2 purchases and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Gilbert Cisneros House, CA, purchase | $1,001 - $15,000 | Oct 12 traded Sep 3 |
| Gilbert Cisneros House, CA, purchase | $15,001 - $50,000 | Sep 11 traded Aug 19 |
From congressional disclosures, which report amounts as ranges.
Globus Medical has been buying back its own shares.
From company filings.
2signals, 0% of the flagged premium in calls.
Latest: Bearish flow on Nov 6, $481K in unusual premium.
Globus Medical reports on Feb 23, 2027, after the close (100 days away), and beat the EPS estimate in 7 of its last 8 reports.
Feb 23, 2027
Expected after the close, 100 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $1.34 est $1.10 | $789.6M est $782.9M | +2.2% |
| May 7, 2026 | $1.12 est $0.92 | $759.9M est $740.3M | −12.6% |
| Feb 24, 2026 | $1.28 est $1.15 | $826.4M est $801.7M | +3.0% |
| Nov 6, 2025 | $1.18 est $0.77 | $769.0M est $734.7M | +36.4% |
| Aug 7, 2025 | $0.86 est $0.75 | $745.3M est $742.7M | +11.0% |
| May 8, 2025 | $0.68 est $0.74 | $598.1M est $625.9M | −21.9% |
| Feb 20, 2025 | $0.84 est $0.75 | $657.3M est $645.7M | −4.5% |
| Nov 5, 2024 | $0.83 est $0.65 | $625.7M est $604.7M | +10.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Globus Medical is $93.43, +29.5% from the last close, from 9 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 9 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 6 | Wells Fargo | $100 | +38.6% |
| Nov 6 | Piper Sandler | $100 | +38.6% |
| Nov 6 | Canaccord Genuity | $105 | +45.6% |
| Nov 6 | BMO Capital | $78 | +8.1% |
| Nov 6 | Bank of America Securities | — | — |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Globus Medical averaged +2.1% across the last 5 years, rising in 4 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.8% | 2 of 5 |
| Next 10 trading days | −0.7% | 3 of 5 |
| Next 15 trading days | −0.6% | 2 of 5 |
| Next 20 trading days | +2.1% | 4 of 5 |
| Next 30 trading days | +5.8% | 5 of 5 |
For scale, GMED’s typical 20-trading-day move in either direction is about 6%.
Globus Medical’s market cap is $9.57B, with a P/E ratio of 17.8 and revenue of $3.14B over the last twelve months.
Coverage of Globus Medical this week reads negative: 1 positive, 1 neutral and 5 negative headlines.
Globus Medical’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| ABTAbbott Laboratories | Neutral | 10.5% below |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
A peer links to its own page where one exists.
Globus Medical’s market cap is $9.57B at the Nov 13, 2026 close of $72.14, with 110.2M shares outstanding. The shares trade on a P/E ratio of 17.8.
The consensus analyst 12-month price target for Globus Medical is $93.43, +29.5% from the last close. Of the 9 firms that rated the stock in the last 90 days, 6 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Globus Medical is about fair value: the Nov 13, 2026 close of $72.14 is 0.1% above Gekko Fair Value of $72.10. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Globus Medical is expected to report on Feb 23, 2027, after the market closes (100 days away). Analysts expect earnings of $1.30 per share on revenue of $783.4M. Globus Medical beat the earnings estimate in 7 of its last 8 reports, moving 12.8% on average across the report.
Globus Medical’s 52-week high is $101.40 and its 52-week low is $70.40; it closed at $72.14 on Nov 13, 2026, −14.8% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (gekkoindex, earnings risk and seasonality), 2 as mixed (fair value and smart money) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.
Gekko flagged 2 unusual options signals in Globus Medical over the last 30 days, with $0 of flagged premium in calls and $945K in puts. The latest, bearish flow, was on Nov 6, 2026 with $481K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.